Natera Settles Class Action Over Prenatal Tests for $8.25 Million

In a landmark case that underscores the complexities and risks associated with prenatal genetic testing, genetic testing company Natera has reached a final settlement of $8.25 million following a class action lawsuit. This lawsuit brought to light significant concerns regarding the reliability of Natera’s noninvasive prenatal tests (NIPT), particularly those marketed under the names Panorama and Vasistera. The settlement was approved by U.S. District Judge Jon Tigar in Oakland, California, and it serves as a crucial reminder of the responsibilities companies hold when providing medical-related products and services.

The lawsuit arose after a 2022 New York Times report revealed alarming statistics about the accuracy of prenatal tests. These tests, designed to screen for genetic disorders such as Down syndrome, were found to produce a high percentage of false positives for rare conditions. For expectant parents, these results can lead to significant emotional distress and critical decision-making about their pregnancies based on potentially misleading information. Given that Natera's tests are noninvasive, requiring only a blood sample, they are often chosen over more invasive methods like amniocentesis, which carries risks of miscarriage and other complications.

Understanding the Class Action Lawsuit

The class action lawsuit against Natera was initiated by consumers who claimed that the company violated multiple consumer protection laws across several states, including California, Florida, Illinois, Maryland, and New Jersey. The plaintiffs argued that Natera misled potential customers by marketing its tests as reliable indicators of fetal abnormalities while being well aware of the high likelihood of false positives.

As part of the settlement, all individuals in the U.S. who purchased at least one of Natera's noninvasive prenatal tests during the class period are eligible to receive compensation. The class period varies by state, commencing as early as February 17, 2016, in Ohio, and extending to February 17, 2018, for other states. This broad inclusion means that many consumers could be impacted, highlighting the prevalence of such tests in prenatal care.

Settlement Details and Consumer Compensation

Judge Tigar characterized the settlement as fair and reasonable, emphasizing that it provides significant recoveries for class members while balancing the risks and costs associated with pursuing further litigation. The settlement agreement includes provisions for attorney fees, which total approximately $2.4 million, and over $200,000 for out-of-pocket expenses. Each of the eight class representatives will receive $7,500 for their roles in the litigation.

Class members who can provide proof of purchase of the test are entitled to receive up to 10% of their expenses if those expenses exceeded $300. For claimants without proof of purchase, a flat sum of up to $30 is available. This compensation structure aims to provide some financial relief to consumers who may have incurred expenses related to these tests, especially in light of the emotional and psychological burdens associated with misleading medical information.

Implications for Genetic Testing and Consumer Protection

The Natera case is emblematic of broader issues in the genetic testing market. As prenatal testing becomes increasingly common, the need for stringent consumer protection regulations is paramount. The settlement does not imply an admission of liability by Natera; however, the company has agreed to enhance transparency in its marketing materials by clearly stating that its prenatal tests are screening tools, not diagnostic tests. This distinction is crucial, as it emphasizes the importance of confirming high-risk screening results with more definitive diagnostic tests.

This legal outcome could reverberate throughout the industry, prompting other companies to reassess how they communicate the capabilities and limitations of their products. As consumers become more aware of the potential pitfalls of genetic testing, manufacturers may face greater scrutiny regarding their marketing practices and the accuracy of their tests.

Challenges in Class Action Notifications

Despite the settlement's approval, the notification process for potential class members has not been without its challenges. Following preliminary approval in December 2025, the settlement administrator, Simpluris, Inc., identified issues in notifying some class members via email and postcards. After a thorough investigation and corrective actions, the deadline for class members to submit claims or opt-out was reset to July, ensuring that over 98% of the settlement class received the necessary information about their eligibility.

The court's insistence on rectifying these notification issues reflects its commitment to ensuring that all affected consumers have a fair opportunity to participate in the settlement. The complexities of managing class action notifications highlight the significant logistical challenges inherent in large-scale legal settlements.

Key Takeaways

• Natera's settlement of $8.25 million addresses concerns over misleading marketing of prenatal tests.
• Consumers eligible for compensation include all individuals who purchased Natera’s tests during the class period.
• The settlement emphasizes the distinction between screening tests and diagnostic tests, urging further verification of high-risk results.
• Class members can claim compensation based on proof of purchase, highlighting the importance of maintaining records.
• This case may influence future regulations and marketing practices within the genetic testing industry.

Frequently Asked Questions

What should I do if I purchased a Natera prenatal test?

If you purchased a Natera prenatal test during the class period (varying by state, from February 17, 2016, to February 17, 2018), you should consider submitting a claim to receive compensation. Make sure to gather any proof of purchase you may have, as this will impact the amount you are eligible to claim. If you do not have proof of purchase, you can still submit a claim for a smaller amount.

Will Natera admit liability as part of the settlement?

No, the settlement does not require Natera to admit any liability. This is a common feature in settlements, allowing companies to resolve disputes without acknowledging wrongdoing. However, Natera has agreed to enhance the transparency of its marketing by clarifying that its tests are screening tools rather than definitive diagnostic tests, which is an important distinction for consumers.

How can this settlement impact the future of genetic testing?

The Natera settlement may set a precedent for how genetic testing companies communicate the reliability of their products. As consumers become more aware of the potential for false positives, particularly in prenatal testing, there may be increased pressure on companies to improve the accuracy of their tests and to provide clearer information about their limitations. This could lead to tighter regulations and guidelines in the genetic testing industry.

What are the risks associated with prenatal tests?

While noninvasive prenatal tests, such as those offered by Natera, are generally considered safer than invasive tests like amniocentesis, they are not without risks. The main concern is the potential for false positives, which can lead to unnecessary anxiety or decisions regarding the pregnancy. Patients are advised to discuss their results with healthcare providers and consider follow-up diagnostic testing for any high-risk findings.